Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Debt to Equity (2016 - 2025)

Guided Therapeutics' Debt to Equity history spans 14 years, with the latest figure at -$0.02 for Q3 2025.

  • For Q3 2025, Debt to Equity rose 92.12% year-over-year to -$0.02; the TTM value through Sep 2025 reached -$0.02, up 92.12%, while the annual FY2024 figure was -$0.03, N/A changed from the prior year.
  • Debt to Equity for Q3 2025 was -$0.02 at Guided Therapeutics, down from -$0.02 in the prior quarter.
  • Across five years, Debt to Equity topped out at -$0.01 in Q1 2021 and bottomed at -$0.25 in Q2 2024.
  • The 4-year median for Debt to Equity is -$0.03 (2022), against an average of -$0.08.
  • The largest annual shift saw Debt to Equity crashed 1894.95% in 2022 before it skyrocketed 93.19% in 2025.
  • A 4-year view of Debt to Equity shows it stood at -$0.12 in 2021, then surged by 72.23% to -$0.03 in 2022, then increased by 2.7% to -$0.03 in 2024, then skyrocketed by 43.86% to -$0.02 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Debt to Equity are -$0.02 (Q3 2025), -$0.02 (Q2 2025), and -$0.02 (Q1 2025).